Becton, Dickinson and Company (BDX)
(Delayed Data from NYSE)
$237.84 USD
+0.54 (0.23%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $237.77 -0.07 (-0.03%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth F Momentum D VGM
Price, Consensus and EPS Surprise
BDX 237.84 +0.54(0.23%)
Will BDX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BDX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BDX
Sustained Product Demand Likely to Aid BD's (BDX) Q3 Earnings
Countdown to Becton Dickinson (BDX) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
BDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Reasons to Retain DENTSPLY SIRONA (XRAY) in Your Portfolio Now
Veeva Systems' (VEEV) Vault EDC to Boost Vita Global's Workflow
Reasons to Add The Cooper Companies (COO) to Your Portfolio Now
Other News for BDX
Key Takeaways From Becton Dickinson Analyst Ratings
Becton Dickinson price target raised by $10 at Stifel, here's why
Becton, Dickinson (BDX) Shares Cross Above 200 DMA
Becton Dickinson, Quest Diagnostics enter collaboration agreement
BD, Quest Diagnostics Join Forces to Develop Companion Diagnostics for Cancer, Other Diseases